0.7302
Intensity Therapeutics Inc Aktie (INTS) Neueste Nachrichten
How interest rate cuts could boost Intensity Therapeutics Inc. stockJuly 2025 PostEarnings & Safe Entry Zone Tips - newser.com
Using Bollinger Bands to evaluate Intensity Therapeutics Inc.Quarterly Performance Summary & Weekly High Return Stock Opportunities - newser.com
How to track smart money flows in Intensity Therapeutics Inc.2025 Winners & Losers & Daily Growth Stock Investment Tips - newser.com
Does Intensity Therapeutics Inc. show high probability of rebound2025 Key Highlights & Precise Buy Zone Tips - newser.com
Ranking Intensity Therapeutics Inc. among high performing stocks via tools2025 Earnings Surprises & High Return Stock Watch Alerts - newser.com
How Intensity Therapeutics Inc. stock performs in stagflationJuly 2025 Review & Low Drawdown Trading Strategies - newser.com
How Intensity Therapeutics Inc. stock trades before earnings2025 Breakouts & Breakdowns & AI Powered Market Entry Strategies - newser.com
Intensity Therapeutics surges 395% on phase 1/2 data for solid tumors asset - MSN
Intensity Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Intensity Therapeutics Enters Securities Purchase Agreement - TipRanks
INTS to raise $4.0M via 5,000,000-share registered direct sale - Stock Titan
Intensity Therapeutics prices $4 million registered direct offering By Investing.com - Investing.com South Africa
Intensity Therapeutics announces pricing of $4M registered direct offering of common stock - MSN
Intensity Therapeutics Prices $4 Million Direct Offering - MarketScreener
Intensity Therapeutics prices 5M shares at 80c in registered direct offering - TipRanks
Intensity Therapeutics shares plunge 30% after $4 million discounted stock offering - MSN
Intensity Therapeutics, Inc. (INTS) stock tumbles 30% as $4M direct offering sparks investor concern - parameter.io
Unexpected Surge: Analyzing INTS Performance - timothysykes.com
Intensity Therapeutics prices $4 million registered direct offering - Investing.com
INTS Stock Price and Chart — NASDAQ:INTS - TradingView
Biotech Bombshell: Intensity Therapeutics (INTS) Surges Nearly 400% on Major Cancer Trial News - ts2.tech
Intensity Therapeutics stock tumbles after pricing $4 million offering By Investing.com - Investing.com Nigeria
Intensity Therapeutics stock tumbles after pricing $4 million offering - Investing.com
Intensity Therapeutics stock up nearly 400% on solid tumour data - Yahoo Finance
Intensity Therapeutics (Nasdaq: INTS) prices $4M registered direct, selling 5M shares - Stock Titan
Is Intensity Therapeutics Inc. stock oversold or undervaluedJuly 2025 Reactions & Consistent Income Trade Recommendations - newser.com
Why Intensity Therapeutics Inc. stock is favored by top institutionsWeekly Market Report & AI Optimized Trade Strategies - newser.com
Trending tickers: Apple, Amazon, Netflix, Reddit and Intensity Therapeutics - Yahoo! Finance UK
Volume spikes in Intensity Therapeutics Inc. stock – what they meanMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com
How to integrate Intensity Therapeutics Inc. into portfolio analysis toolsEarnings Miss & Verified Trade Idea Suggestions - newser.com
Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know - inkl
US Stock Market top gainers and losers on October 30: Intensity Therapeutics, Inc. sees nearly 400% jump, - The Economic Times
Positive Phase 1/2 clinical data for cancer candidate drug propels Intensity Therapeutics (INTS.US) stock up by 395%. - 富途牛牛
Why Is Retail Going Gaga Over INTS Stocks Today? - Stocktwits
Intensity Therapeutics Shares Soar on Promising Cancer Trial Results - El-Balad.com
Intensity Therapeutics publishes cancer treatment study results in Lancet journal By Investing.com - Investing.com South Africa
Intensity Therapeutics shares skyrocket after strong cancer drug trial results - Business Upturn
Intensity Therapeutics shares more than double on promising cancer trial data - TradingView
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):